NCT07008885 is a Phase 1, PHASE2 clinical trial of CAR19TIF cells in Acute Lymphocytic Leukemia, sponsored by Chinese PLA General Hospital.

Who is sponsoring NCT07008885?

NCT07008885 is sponsored by Chinese PLA General Hospital.

What drugs are being tested in NCT07008885?

Interventions in NCT07008885: CAR19TIF cells, Fludarabine, Cyclophosphamide.

What condition does NCT07008885 study?

NCT07008885 studies Acute Lymphocytic Leukemia.

Is NCT07008885 still recruiting?

NCT07008885 is currently recruiting now. Last updated 25 June 2025.

Last reviewed 2025-06-25 · How we verify

NCT07008885

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL

Recruiting now Phase 1, PHASE2 Last updated 25 June 2025

What this trial tests

Phase 1, PHASE2 trial testing CAR19TIF cells in Acute Lymphocytic Leukemia in 30 participants. Currently enrolling.

Timeline

20 June 2025

Primary endpoint
31 May 2026

31 May 2027

Quick facts

Lead sponsor	Chinese PLA General Hospital
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	20 June 2025
Primary completion	31 May 2026
Estimated completion	31 May 2027
Sites	2 locations across China

Drugs / interventions tested

CAR19TIF cells — full drug profile →
Fludarabine (FLUDARABINE) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

Acute Lymphocytic Leukemia — all drugs for Acute Lymphocytic Leukemia →

Sponsor

Chinese PLA General Hospital

Who can join

Adults 18 to 70, any sex, with Acute Lymphocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this single-center, single-arm, prospective, Phase 1/2 study, the safety and efficacy of autologous BCOR and ZC3H12 genes knock-out CD19-targeting chimeric antigen receptor (CAR) T-cell therapy will be evaluated in patients with refractory/relapsed (r/r) B-cell acute lymphoblastic leukaemia (B-ALL). In phase 1, 3 eligible patients will be enrolled and receive BCOR and ZC3H12 genes knock-out CD19 CAR T cell therapy at a initial dose of 5×10\^5 cells/kg. Based on the results, . Subsequently an additional 3-15 patients will be enrolled in a "3+3" dose-escalation/decline design to adjust the dose of BCOR and ZC3H12 genes knock-out CD19 CAR T cells to achieve optimal safety and efficacy. The recommended Phase 2 dose (RP2D) will then be established. 10 to 12 subjects will be enrolled and receive BCOR and ZC3H12 genes knock-out CD19 CAR T cell infusion at dose of RP2D.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108

Verify or expand the search:

Other trials of CAR19TIF cells

Trials testing the same drug.

NCT07009002 — BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma · Phase 1, PHASE2 · recruiting

Other recruiting trials for Acute Lymphocytic Leukemia

Currently open trials in the same condition.

NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
NCT06481735 — TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL · Phase 1, PHASE2 · recruiting
NCT06476665 — A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia. · active not recruiting
NCT06783816 — A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors · NA · recruiting
NCT06131801 — Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution · recruiting

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07008885 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
Last refreshed: 25 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07008885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing